VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #4 WG-am: A Novel Antiviral Dipeptide from Elite Controllers as a Promising Vaginal Microbicide for HIV Prevention - Rafael Ceña DiezView Video
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #3 Unveiling Novel Microbiome Signatures for Natural Virological Control in HIV-1 Elite Controllers - Xiangning BaiView Video
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #2 In Addition to Their Ability to Induce Resistance to Antiretrovirals, Integrase Inhibitors and Lenacapavir Resistance Mutations Enable HIV-1 to Evade Recognition by the Innate Immune System - Elisa TeyssouView Video
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #1 Comparable Dynamics of Cell-Associated HIV-RNA, Total and Intact Proviral HIV-1 DNA in Virologically Suppressed People with HIV Switching to 2DR or Continuing 3DR Over an 18-Month Follow-Up - Lia FiaschiView Video
JAJuan AmbrosioniMD, PhDVideoHIV23rd European Meeting on HIV & Hepatitis 2025Efficacy, Toxicity and Adherence Considerations - Juan AmbrosioniView Video
JDJohn DitekemenaMD, MPH, PhDVideoTuberculosis2nd Conference on Innovations in Tuberculosis 2025Towards Integrated Prevention, Treatment, and Service Provision for TB, HIV and NCDs - John DitekemenaView Video
BdJBouke de JongMSc, PhDVideoTuberculosis2nd Conference on Innovations in Tuberculosis 2025Should Africa Move to Whole Genome Sequencing for Drug Resistance Testing? Con Standpoint - Bouke de JongView Video
VideoTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #17 Economic Recovery Among Patients Following Drug-Susceptible Tuberculosis Treatment in Johannesburg, South Africa - Kamban HirasenView Video
VideoTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #49 Managing TB/HIV Comorbidities Among Children and Adolescents Co-Infected With TB & HIV Through Targeted Structural Interventions in Northern Nigeria: A Pathway to Improved Health Outcomes - Charles OdimaView Video
VideoTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #34 Comparative Pharmacokinetics of Dolutegravir in Children With HIV With and Without TB Co-Infection - Charles Martyn-DickensView Video
VideoTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #12 Impact of Mycobacterium tuberculosis Strains With rpoB I491F Mutation on Uptake and Outcomes of BPaLM Regimen in Eswatini - Debrah VambeView Video
VideoTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #25 Evaluating Targeted Next-Generation Sequencing for Diagnosing Drug-Resistant Tuberculosis in Namibia - Lusia MhuuluView Video
